WHETHER CHIDAMIDE IMPROVES THE RESPONSE TO CISPLATIN IN FIRST-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER

被引：0

作者：

Zhang, Jian ^{[1
]}

Hu, Xichun ^{[1
]}

Meng, Yanchun ^{[1
]}

Jin, Juan ^{[1
]}

Gong, Chengcheng ^{[1
]}

Miao, Haitao ^{[1
]}

Tao, Zhonghua ^{[1
]}

Li, Ting ^{[1
]}

Cao, Jun ^{[1
]}

Wang, Leiping ^{[1
]}

Wang, Biyun ^{[1
]}

Hu, Xichun ^{[1
]}

机构：

[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

来源：

BREAST | 2021年 / 59卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO56

引用

页码：S46 / S46

页数：1

共 50 条

[41] Efficacy of first-line bevacizumab (BEV)-based therapy for metastatic triple-negative breast cancer (TNBC): Subgroup analysis of TURANDOT
Inbar, Moshe J.
Lang, Istvan
Kahan, Zsuzsanna
Greil, Richard
Beslija, Semir
Stemmer, Salomon M.
Kaufman, Bella
Ahlers, Silke
Brodowicz, Thomas
Zielinski, Christoph
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[42] Chidamide Reverses Fluzoparib Resistance in Triple-Negative Breast Cancer Cells
Li, Xinyang
Yuan, Xiang
Wang, Ziming
Li, Jing
Liu, Zhiwei
Wang, Yukun
Wei, Limin
Li, Yuanpei
Wang, Xinshuai
FRONTIERS IN ONCOLOGY, 2022, 12
[43] Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy
Mitri, Z. I.
Ueno, N. T.
Yang, W.
Valero, V.
Litton, J. K.
Murthy, R. K.
Ibrahim, N. K.
Arun, B. K.
Mittendorf, E. A.
Hunt, K. K.
Meric-Bernstam, F.
Thompson, A.
Piwnica-Worms, H.
Tripathy, D.
Symmans, F.
Moulder-Thompson, S.
CANCER RESEARCH, 2016, 76
[44] Women's triple-negative, first-line treatment: Improving outcomes in triple-negative breast cancer using molecular triaging and diagnostic imaging to guide neoadjuvant therapy
Mitri, Zahi
Ueno, Naoto T.
Yang, Wei
Valero, Vicente
Litton, Jennifer K.
Murthy, Rashmi
Lim, Bora
Ibrahim, Nuhad K.
Arun, Banu K.
Mittendorf, Elizabeth A.
Hunt, Kelly K.
Meric-Bernstam, Funda
Thompson, Alastair
Gilcrease, Michael
Piwnica-Worms, Helen
Tripathy, Debasish
Symmans, William Fraser
Moulder-Thompson, Stacy
CANCER RESEARCH, 2016, 76
[45] Highly Effective of Gemcitabine and Cisplatin (GP) as First-Line Combination Therapy in Patients with Triple-Negative Metastatic Breast Cancer: Final Report of a Phase II Trial.
Wang, Z.
Hu, X.
Wang, B.
Wang, L.
Zhang, J.
Wang, H.
Liu, G.
Hu, Z.
Wu, J.
Shao, Z.
CANCER RESEARCH, 2011, 71
[46] Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer
Huang, Min
Fasching, Peter
Haiderali, Amin
Pan, Wilbur
Gray, Emma
Zhou, Zheng-Yi
Hu, Peter
Chaudhuri, Mitashri
De Tilleghem, Celine Le Bailly
Cappoen, Nicolas
O'Shaughnessy, Joyce
IMMUNOTHERAPY, 2022, 14 (13) : 1027 - 1041
[47] FUTURE-SUPER: A randomized, subtyping-based umbrella phase II trial for first-line treatment of metastatic triple-negative breast cancer
Shao Zhimin
Fan, Lei
Ma Linxiaoxi
Wu, Songyang
Chen, Li
Liu, Xiyu
Zhang, Wenjuan
Hu, Xin
Jiang, Yizhou
Wang, Zhonghua
Li, Huajun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[48] Pretreatment 18F-FDG Uptake Heterogeneity Predicts Treatment Outcome of First-Line Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer
Gong, Chengcheng
Ma, Guang
Hu, Xichun
Zhang, Yingjian
Wang, Zhonghua
Zhang, Jian
Zhao, Yannan
Li, Yi
Xie, Yizhao
Yang, Zhongyi
Wang, Biyun
ONCOLOGIST, 2018, 23 (10): : 1144 - 1152
[49] Atezolizumab for metastatic triple-negative breast cancer
Stirrups, Robert
LANCET ONCOLOGY, 2018, 19 (10): : E519 - E519
[50] Iniparib in Metastatic Triple-Negative Breast Cancer
Domagala, Pawel
Lubinski, Jan
Domagala, Wenancjusz
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (18): : 1780 - 1780

← 1 2 3 4 5 →